Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Soluble forms of tau are toxic in Alzheimer's disease.

Kopeikina KJ, Hyman BT, Spires-Jones TL.

Transl Neurosci. 2012 Sep;3(3):223-233.

2.

Are tangles as toxic as they look?

Spires-Jones TL, Kopeikina KJ, Koffie RM, de Calignon A, Hyman BT.

J Mol Neurosci. 2011 Nov;45(3):438-44. doi: 10.1007/s12031-011-9566-7. Epub 2011 Jun 3. Review. Erratum in: J Mol Neurosci. 2011 Nov 45(3):742.

3.

[Drug development for tauopathy and Alzheimer's disease].

Takashima A.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):177-80. Review. Japanese.

PMID:
20857696
4.

Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.

Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I, Fernandez-Carballo L, de Munain EL, Perez J, Marquie M, Serrano-Pozo A, Frosch MP, Lowe V, Parisi JE, Petersen RC, Ikonomovic MD, López OL, Klunk W, Hyman BT, Gómez-Isla T.

Brain. 2013 Aug;136(Pt 8):2510-26. doi: 10.1093/brain/awt171. Epub 2013 Jul 3.

5.

Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain.

Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, Luebke JI, Koffie RM, Frosch MP, Hyman BT, Spires-Jones TL.

Am J Pathol. 2011 Oct;179(4):2071-82. doi: 10.1016/j.ajpath.2011.07.004. Epub 2011 Aug 18.

6.

Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.

Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM, Trojanowski JQ.

Brain. 2012 Mar;135(Pt 3):807-18. doi: 10.1093/brain/aws013.

7.

[Significance of tau in the development of Alzheimer's disease].

Takashima A.

Brain Nerve. 2010 Jul;62(7):701-8. Review. Japanese.

PMID:
20675874
8.

Tau aggregates as immunotherapeutic targets.

Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R.

Front Biosci (Schol Ed). 2013 Jan 1;5:426-38. Review.

PMID:
23277060
9.

Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.

Graham DL, Gray AJ, Joyce JA, Yu D, O'Moore J, Carlson GA, Shearman MS, Dellovade TL, Hering H.

Neuropharmacology. 2014 Apr;79:307-13. doi: 10.1016/j.neuropharm.2013.11.025. Epub 2013 Dec 8.

PMID:
24326295
10.

Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.

Pei JJ, Sjögren M, Winblad B.

Curr Opin Psychiatry. 2008 Nov;21(6):555-61. doi: 10.1097/YCO.0b013e328314b78b. Review.

PMID:
18852562
11.

Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.

Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R.

Curr Alzheimer Res. 2011 Sep;8(6):659-65. Review.

PMID:
21605039
12.

Caspase activation precedes and leads to tangles.

de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT.

Nature. 2010 Apr 22;464(7292):1201-4. doi: 10.1038/nature08890. Epub 2010 Mar 31.

13.
14.

Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles.

Guo JL, Lee VM.

J Biol Chem. 2011 Apr 29;286(17):15317-31. doi: 10.1074/jbc.M110.209296. Epub 2011 Mar 3.

15.

Synaptic changes in Alzheimer's disease and its models.

Pozueta J, Lefort R, Shelanski ML.

Neuroscience. 2013 Oct 22;251:51-65. doi: 10.1016/j.neuroscience.2012.05.050. Epub 2012 Jun 9. Review.

PMID:
22687952
16.

Tau aggregation is a therapeutic target for Alzheimer's disease.

Takashima A.

Curr Alzheimer Res. 2010 Dec;7(8):665-9. Review.

PMID:
20678070
17.
18.

Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies.

Wilhelmus MM, de Jager M, Rozemuller AJ, Brevé J, Bol JG, Eckert RL, Drukarch B.

J Pathol. 2012 Jan;226(1):132-42. doi: 10.1002/path.2984. Epub 2011 Oct 18.

19.

Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein.

Feuillette S, Miguel L, Frébourg T, Campion D, Lecourtois M.

J Neurochem. 2010 May;113(4):895-903. doi: 10.1111/j.1471-4159.2010.06663.x. Epub 2010 Feb 27.

20.

Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.

Bloom GS.

JAMA Neurol. 2014 Apr;71(4):505-8. doi: 10.1001/jamaneurol.2013.5847. Review.

PMID:
24493463

Supplemental Content

Support Center